Black Rock Inc. Morpho Sys Ag Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Morpho Sys Ag stock. As of the latest transaction made, Black Rock Inc. holds 1,017,852 shares of MOR stock, worth $18.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,017,852

Previous 864,600 17.73%

Holding current value

$18.5 Million

Previous $8.56 Million 115.71%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$8.6 - $18.18 $1.32 Million - $2.79 Million	153,252 Added 17.73%	1,017,852 $18.5 Million
Q4 2023 Feb 13, 2024	BUY	$4.55 - $9.9 $3.73 Million - $8.12 Million	820,608 Added 1865.36%	864,600 $8.56 Million
Q3 2023 Nov 13, 2023	BUY	$6.72 - $8.6 $63,114 - $80,771	9,392 Added 27.14%	43,992 $295,000
Q2 2023 Aug 11, 2023	BUY	$3.95 - $7.74 $52,629 - $103,127	13,324 Added 62.62%	34,600 $258,000
Q1 2023 May 12, 2023	SELL	$3.56 - $5.22 $8,672 - $12,715	-2,436 Reduced 10.27%	21,276 $84,000

Q4 2022 Feb 13, 2023	BUY	$3.21 - $5.74 $27,272 - $48,767	8,496 Added 55.84%	23,712 $84,000
Q3 2022 Nov 14, 2022	SELL	$4.14 - $22.13 $178,599 - $954,688	-43,140 Reduced 73.93%	15,216 $77,000
Q2 2022 Aug 12, 2022	SELL	$4.51 - $7.39 $351,013 - $575,163	-77,830 Reduced 57.15%	58,356 $282,000
Q1 2022 May 12, 2022	SELL	$5.87 - $9.73 $342,103 - $567,064	-58,280 Reduced 29.97%	136,186 $923,000
Q4 2021 Feb 10, 2022	SELL	$9.08 - $12.45 $6 Million - $8.23 Million	-660,672 Reduced 77.26%	194,466 $1.83 Million
Q3 2021 Nov 09, 2021	BUY	$11.76 - $19.51 $956,334 - $1.59 Million	81,321 Added 10.51%	855,138 $10.1 Million
Q2 2021 Aug 11, 2021	BUY	$18.95 - $23.95 $14.7 Million - $18.5 Million	773,817 New	773,817 $14.9 Million

Others Institutions Holding MOR

# of Institutions

Shares Held

11.3M

Call Options Held

320K

Put Options Held

1.1M

View Full List

About MorphoSys AG

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Market Cap $2.49B
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

More about MOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account